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Abstract
Introduction: Mucopolysaccharidosis (MPS) IVA or Morquio A syndrome is an autosomal recessive lysosomal storage
disorder (LSD) caused by deficiency of the N-acetylgalactosamine-6-sulfatase (GALNS) enzyme, which impairs lysosomal
degradation of keratan sulphate and chondroitin-6-sulphate. The multiple clinical manifestations of MPS IVA present
numerous challenges for management and necessitate the need for individualised treatment. Although treatment
guidelines are available, the methodology used to develop this guidance has come under increased scrutiny. This
programme was conducted to provide evidence-based, expert-agreed recommendations to optimise management of
MPS IVA.
Methods: Twenty six international healthcare professionals across multiple disciplines, with expertise in managing MPS
IVA, and three patient advocates formed the Steering Committee (SC) and contributed to the development of this
guidance. Representatives from six Patient Advocacy Groups (PAGs) were interviewed to gain insights on patient
perspectives. A modified-Delphi methodology was used to demonstrate consensus among a wider group of
healthcare professionals with experience managing patients with MPS IVA and the manuscript was evaluated against
the validated Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument by three independent
reviewers.
Results: A total of 87 guidance statements were developed covering five domains: (1) general management principles;
(2) recommended routine monitoring and assessments; (3) disease-modifying interventions (enzyme replacement
therapy [ERT] and haematopoietic stem cell transplantation [HSCT]); (4) interventions to support respiratory and sleep
disorders; (5) anaesthetics and surgical interventions (including spinal, limb, ophthalmic, cardio-thoracic and ear-nose-
throat [ENT] surgeries). Consensus was reached on all statements after two rounds of voting. The overall guideline
AGREE II assessment score obtained for the development of the guidance was 5.3/7 (where 1 represents the lowest
quality and 7 represents the highest quality of guidance).
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Conclusion: This manuscript provides evidence- and consensus-based recommendations for the management of
patients with MPS IVA and is for use by healthcare professionals that manage the holistic care of patients with the
intention to improve clinical- and patient-reported outcomes and enhance patient quality of life. It is recognised that
the guidance provided represents a point in time and further research is required to address current knowledge and
evidence gaps.
Keywords: Morquio a syndrome, Mucopolysaccharidosis, MPS IVA, Management guidelines, Elosulfase alfa, VIMIZIM,
Enzyme replacement therapy, ERT, Haematopoietic stem cell transplantation, HSCT, Surgery, Anaesthetics
Background
Mucopolysaccharidoses (MPS) are a clinically hetero-
geneous group of rare metabolic disorders referred to as
lysosomal storage disorders (LSDs). MPS disorders arise
due to deficiencies in enzymes that break down glyco-
saminoglycans (GAGs) [1–3]. The build-up of GAGs,
either directly or indirectly, cause progressive damage to
cells, tissues and various organ systems and result in
severe morbidity and reduced life expectancy [4, 5].
Clinical features that are common to all MPS disorders
include skeletal and joint abnormalities, dysfunction in
vision and hearing, cardiorespiratory problems, hepato-
splenomegaly and coarse features [1]. Changes in the
central nervous system are characteristic of some of
these disorders, with typical imaging findings including
white matter lesions, hydrocephalus, cervical spinal canal
stenosis and bone abnormalities of the skull and spine [6].
MPS IVA or Morquio A syndrome (253000) is an auto-
somal recessive MPS disorder caused by deficiency of the
N-acetylgalactosamine-6-sulfatase (GALNS) enzyme (EC
3.1.6.4), which impairs lysosomal degradation of keratan
sulphate and chondroitin-6-sulphate [7–11]. Results of a
systematic review indicate that the point prevalence of
MPS IVA was 1 per 926,000 in Australia, 1 per 1,872,000
in Malaysia and 1 per 599,000 in the UK [12]. Many
genetic mutations have been identified and are responsible
for the heterogeneous clinical presentation, which make
diagnosis challenging. Although elevated urinary GAGs or
reduced GALNS activity in dried blood spot results may
be indicative of MPS IVA, a definite diagnosis is often
only achieved through demonstration of reduced
GALNS activity in leukocytes or fibroblasts or with mo-
lecular confirmation of two disease-causing mutations
in the GALNS gene [13].
MPS IVA is a heterogeneous and progressive disorder.
Skeletal and joint abnormalities including genu valgum,
joint hypermobility, hip subluxation and dysplasia, spinal
cord compression, spinal instability and thoracolumbar
kyphoscoliosis are the most prevalent manifestations [8,
14–16], and patients require regular assessment of multi-
organ involvement [17]. Respiratory impairment and
spinal cord instability are the main cause of morbidity and
mortality [14, 18, 19] and cardiac dysfunction has also
been reported [20]. Other manifestations include corneal
clouding and hearing loss.
Objectives
This manuscript provides robust guidance for the man-
agement of adult and paediatric patients with MPS IVA
using a validated modified-Delphi methodology to gain
consensus. The guidance is comprised of a holistic set of
recommendations for the timely and appropriate use of
medical and surgical interventions and management of
the natural history of MPS, with the intention to main-
tain and enhance patient quality of life with the
intention to maintain and enhance patient quality of life
(QoL) and improve and improve clinical- and patient re-
ported- outcomes. The guidance is intended for use by
healthcare professionals that manage the care of patients
with MPS IVA, in particular paediatricians and geneti-
cists, and aims to enhance multidisciplinary practice
across specialities. It also provides specific guidance for
other specialists (Table 1) and stakeholders in the health
services who are in contact with patients with MPS and
is a useful reference for patient advocates, patients and
their families. Table 1 describes the areas of clinical
focus covered within this guidance and the correspond-
ing recommended speciality focus.
This guidance was developed as part of a broader con-
sensus programme that also covered the management of
MPS VI, the results of which are published in a compan-
ion article (Recommendations for the management of MPS
VI: systematic evidence- and consensus-based guidance).
Methods and process
The methods described below cover both MPS IVA and MPS
VI; however, the results section focuses on MPS IVA only.
Convening of the steering committee
Four steering committee (SC) Co-Chairs were appointed
using a systematic expert mapping approach based on a
ranking measure of publication/congress activity rele-
vant to the management of MPS IVA/VI and leadership
roles in editorial boards and professional bodies. The
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Co-Chairs made recommendations for 22 SC members
from across the world, including experts in: anaesthesia,
ear nose and throat (ENT) surgery, cardiology, genetics,
endocrinology, hand surgery, HSCT, neurosurgery, oph-
thalmology, orthopaedic surgery, paediatrics, pain man-
agement and pulmonology. To ensure the patient view
was represented, three members from Patient Advocacy
Groups (PAGs) formed part of the SC group. The SC de-
fined the scope of the programme, including the medical
and surgical interventions to be covered in the guidance
and provided search terms for the literature review. Fur-
ther details, including the competing interests, institu-
tions and contributions of each SC member are listed
within the declarations section of this manuscript.
Setting the clinical questions to be addressed by the guidance
The clinical questions to be addressed by the guidance
were developed by the SC group according to the pa-
tient, interventions, comparator and outcome (P.I.C.O.)
methodology (Additional file 1: Appendix 1a) and are
shown below.
1. What are the general principles for the management
of adult and paediatric patients with MPS IVA/VI?
2. What are the recommended routine monitoring
and assessments that should be used to track the
natural history of adult and paediatric patients with
MPS IVA/VI and indicated interventions to be used
during the care of the common symptoms of MPS?
3. For adult and paediatric patients with MPS IVA/VI,
what is the impact on clinical outcomes and safety/
tolerability of:
 Interventions that address the underlying enzyme
deficiency including:
 ERT
 HSCT
 Interventions used to manage the symptoms of MPS
IVA/VI including:
 Respiratory and sleep disorders
 Anaesthesia
 Limb and spinal surgeries
 Ophthalmic surgeries
 Cardio-thoracic surgeries
 ENT surgeries
A secondary focus of the programme was to highlight
current evidence gaps and provide recommendations for
future treatment directions. Topics that were deemed
out of scope of this programme included: comprehensive
recommendations for diagnosis (e.g. screening, testing
and identification of differential disease phenotypes),
validation of new clinical outcome assessment tools (e.g.
to assess patient-reported outcomes) and defining mi-
nimal clinically important differences for MPS IVA/VI.
Patient Advocacy Groups insights
Consultations were conducted with representatives from
six global PAGs (including Brazil, Canada, Germany,
Turkey, the United Kingdom and the United States)
[listed in the acknowledgements section of the manu-
script]. To gain an understanding of the experience and
views of patients with MPS IVA/VI on the holistic ma-
nagement of MPS across several geographies and health-
care systems, the consultations addressed: the biggest
challenges faced by patients with MPS IVA/VI; the
Table 1 Clinical areas of focus and recommended speciality focus
Table Recommended speciality focus
Table 2: General principles for the management of patients with MPS IVA all
Table 3: Recommended routine monitoring and assessments in patients
with MPS IVA
all
Table 4: Guidance statement for elosulfase alfa geneticist, metabolic physician, paediatrician, nurse, physiotherapist
Table 5: Guidance statement for HSCT anaesthetist, bone marrow transplant expert/hematopoietic stem cell
transplant expert, geneticist, paediatrician, nurse
Table 6: Guidance statements for CPAP, NIPPV, oxygen supplementation
and hypercapnia monitoring
anaesthetist, ear-nose-throat specialist, geneticist, paediatrician,
respiratory physician/pulmonologist, nurse
Table 7: Guidance statements for anaesthesia all
Table 8: Guidance statements for hip reconstruction, hip replacement and
growth modulation surgeries
anaesthetist, geneticist, orthopaedic surgeon, neurosurgeon,
paediatrician, physiotherapist
Table 9: Guidance statements for decompression of the spinal cord, spinal
stabilisation and thoracolumbar kyphoscoliosis
anaesthetist, geneticist, orthopaedic surgeon, neurosurgeon,
paediatrician, physiotherapist
Table 10: Guidance statement for corneal transplantation anaesthetist, geneticist, ophthalmologist, paediatrician
Table 11: Guidance statement for cardiac valve replacement anaesthetist, cardiologist, geneticist, paediatrician
Table 12: Guidance statements for tonsillectomy and/or adenoidectomy,
tracheostomy and insertion of ventilation tubes
anaesthetist, geneticist, ear-nose-throat specialist, paediatrician,
respiratory physician/pulmonologist
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impact of medical/surgical interventions on patient
outcomes, including: physical function/performance,
mental/emotional outcomes and socioeconomic out-
comes/cost implications; the overall benefit/risk profile
associated with medical/surgical interventions and how
this influences patient choice; barriers to the use of
medical/surgical interventions across each region (e.g.
reimbursement challenges, cost issues, access issues
etc) and facilitators and barriers for application of
the guidance.
Systematic literature review methodology
A systematic literature review was independently con-
ducted by three Biographical Fellows in accordance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement [21]. The focus
of the literature review was to collate evidence for the
clinical questions. Owing to the nature of the re-
commendations for general principles and routine moni-
toring and assessments, the associated guidance is
predominantly based on clinical opinion; however, where
available, published evidence has been applied to sup-
port these statements.
Literature searches were performed in July 2017 using
PubMed, Web of Science, SCOPUS and the Cochrane
Database of Systematic Reviews; no early date limit was
set. Supplementary searches of Google Scholar were
undertaken to identify recent publications. Search strings
incorporated Medical Subject Headings and free text
key words, and were defined based on the P.I.C.O.
methodology to answer each of the clinical questions
(Additional file 1: Appendix 1a) [22]. Reproducible
search strategies were reviewed by the SC (Additional
file 1: Appendix 1b). As part of the screening, duplicates
were removed. Exclusion criteria included: in-vitro/animal
studies, non-English language studies, studies that did not
report an outcome, diagnosis studies, non-systematic re-
view articles and studies that did not relate to a specific
intervention. Only studies conducted in humans were
included and evidence was extrapolated from other MPS
types. Single case studies were captured and referred to
where evidence was scarce. The bibliographies of identi-
fied pre-existing guidelines and review articles were
checked for additional relevant studies. The following
information was extracted from included studies: refer-
ence details, patient population, intervention, comparator
(where applicable), outcomes (physical function/perfor-
mance, mental/emotional, socioeconomic), safety and
tolerability and reported study limitations. Data were
extracted by one Bibliographic Fellow and checked by a
second. Any discrepancies in screening and data extrac-
tion were resolved through discussion or the intervention
of a third reviewer. Results were reported according to
PRISMA (Additional file 1: Appendices 1b and 1c).
The quality of evidence level for each paper was
assessed using the Oxford Centre for Evidence-based
Medicine (OCEM) criteria. In accordance with the criteria
(Additional file 1: Appendix 2) each reference obtained
from the systematic literature review was critically
appraised and designated an evidence level based on
the study design, rigour of methodology and out-
comes (Additional files 2 and 3). The recommenda-
tion statements were then graded based on the
average evidence level for each supporting reference
(Additional files 2 and 3). The evidence levels and
grades were cross-checked by the SC group and used
to assess the strength of each recommendation during
the development of the guidance statements.
Development and validation of guidance statements
For each clinical area of focus and intervention, the SC
developed draft guidance statements accompanied by
supporting text, which were based on the results of the
literature search, insights from the PAG interviews and
expert clinical opinion. This process was facilitated by
an independent secretariat via a series of face-to-face
and online meetings and email correspondence across a
14-month period.
Guidance statements were ratified using a modified-
Delphi voting process via an online survey [23, 24]. To
ensure specialists were engaged from a wide range of
geographies and across numerous medical and surgical
specialities, the survey containing all guidance state-
ments was sent by the independent secretariat to 197
MPS physicians across 35 clinical areas of focus in 24
countries. Three reminders were sent requesting survey
participation across a three-week open voting period.
Participation in the survey was voluntary and anony-
mous to eliminate bias (a summary of respondents by spe-
cialities and country can be found within Additional files 4
and 5). The names of respondents were not collected;
however, respondents were required to provide infor-
mation pertaining to their hospital/institution, special-
ity, country, years’ experience in the management of
MPS patients and number of MPS IVA and MPS VI
patients they manage/have managed. Respondents were
required to meet a minimum threshold of experience in
the management of patients with MPS, which was
determined by the SC prior to the initiation of the sur-
vey to be: (1) for metabolic specialists: at least 5 years’
experience of managing numerous patients with MPS
(preferably MPS IVA/VI); (2) for specialist surgeons/
anaesthetists: at least 3 years’ experience of managing
numerous patients with MPS (preferably MPS IVA/VI).
Respondents were asked to vote on statements within
their area of expertise only and were able to opt-out of
statements outside of their scope of medical practice spe-
ciality. Guidance statements were voted on using a Likert
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scale from 1 (strongly disagree) to 9 (strongly agree).
Scores of 6 or less were defined as disagreement with the
statement and it was mandatory for respondents to
provide rationale for their disagreement and suggest
amendments to the statement. Scores of 7 or more were
defined as agreement with the statement and respondents
were given the option to add comments.
Consensus was reached when ≥75% of respondents
agreed with a given statement. This consensus threshold
was determined by review of literature and applied to
the rare disease field by the Steering Committee group.
The most commonly reported definition of consensus
for Delphi studies is percent agreement, with 75% being
the median threshold to define consensus [24].
Statements for which consensus was not achieved in
the first round of voting were amended by the SC based
on respondent feedback and expert clinical opinion and
sent for re-voting. The percentage consensus and
assigned evidence grade for each guidance statement is
shown within the results section below.
The quality of study reporting in this programme was
independently assessed by three reviewers using the A-
ppraisal of Guidelines for Research and Evaluation
(AGREE) II Instrument (declared in the acknowledge-
ments section of the manuscript) [25].
Measures to ensure independence
The programme was funded by BioMarin; the manufac-
turer of the recombinant enzymes used to treat MPS
IVA and MPS VI, however, they were not involved in
any stages of the process and did not influence the scope
or content of the programme. BioMarin were absent
from all SC meetings, were blinded to the guidance
statements and were not involved in the publication
process. The programme was managed by an independ-
ent secretariat (Lucid Partners Ltd), and the scope of the
programme and content, including the development of
guidance statements, was led by the SC with editorial
support provided by the secretariat. The SC was iden-
tified through a systematic expert mapping process,
conducted independently of the funder. Conflicts of in-
terests for all SC members (shown in the declarations
section) were recorded at the start of the consensus
programme and updated throughout the programme.
Following the systematic expert mapping exercise, it was
noted that some of the SC had previously worked on a
consultancy basis with the programme sponsor, who
hold the marketing authorisation for approved phar-
maceutical therapy in MPS IVA. Efforts were therefore
taken to ensure representation from leading experts
across other treatment modalities, including HSCT/
BMT on the Steering Committee panel and during the
modified-Delphi voting process, where a large number
of physicians across multiple specialities and geographies
were engaged. At several stages during the process, the
SC were also required to provide updated conflict of
interest disclosures.
Results
Here we report the results relevant to the management
of patients with MPS IVA. The results for MPS VI are
published in a companion article (Recommendations for
the management of MPS VI: systematic evidence- and
consensus-based guidance).
Patient Advocacy Groups insights
The results of the PAG consultations highlighted that
the biggest current unmet needs and challenges faced
for patients with MPS IVA/VI include: treatment expert-
ise, timing and access to treatment, appropriate infra-
structure, maintenance of independence and social
prejudice. The results also summarised the factors that
affect patient prognosis and QoL, key considerations for
all surgical interventions with an emphasis of anaesthe-
sia, barriers to use of medical/surgical interventions and
patient and caregiver considerations.
Detailed insights from all PAG consultations were pre-
sented to the SC group by the patient advocates who
formed part of the SC and were used to inform the
development of the guidance statements and ensure re-
presentation of the patient voice. These insights assisted
with the development of the general principles for
management of patients with MPS IVA/VI, and ensured
holistic care was considered across the whole guidance
development process.
Modified-Delphi results
The modified-Delphi survey contained 116 guidance
statements covering both MPS IVA and VI; only the
MPS IVA statements are described below (Tables 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12). In round one of the
modified-Delphi voting, the online survey was sent to
197 MPS physicians (nominated by the SC group),
including all members of the SC. A total of 103 sub-
missions were received from 82 institutions across 20
countries (further information including the number of
respondents/statements, respondent specialities and geo-
graphies, and respondent feedback to guidance statements
are included within Additional file 4). Seven respondents
did not meet the minimum threshold of experience and
their submissions were excluded. According to the
consensus criteria threshold of 75%, 103/116 statements
reached consensus (Additional file 4). The guidance state-
ments that did not reach consensus were reviewed by the
SC and amended based on feedback from the modified-
Delphi participants and expert clinical opinion.
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In round two of the modified-Delphi voting, 13
statements were sent for re-voting to 145 MPS physi-
cians (experts of specialties not relevant to these state-
ments were removed from the mailing list). A total of
71 survey submissions were received from 53 institu-
tions across 18 countries and two respondents did not
meet the minimum experience threshold and their
submissions were excluded (further information in-
cluding the number of respondents/statements, re-
spondent specialities and geographies, and respondent
feedback to guidance statements are including within
Additional file 5). Consensus was reached on all 13
statements (Additional file 5). In total, 87 guidance
statements reached consensus for MPS IVA.
Appraisal of Guidelines for Research and Evaluation
(AGREE) II assessment
The methodological rigour and transparency employed
within the development of this guidance was evaluated
through the review of the manuscripts against the validated
AGREE II instrument. Three independent reviewers [listed
in the acknowledgements section of the manuscript]
assessed the manuscript and suggested amendments were
addressed where possible; a subsequent second round of re-
view was conducted by all reviewers. Across each AGREE
II criteria, the average domain scores obtained were: scope
and purpose (85%), stakeholder involvement (85%), rigour
of development (73%), clarity of presentation (78%), applic-
ability (34%) and editorial independence (64%) (full infor-
mation including the scores from the two rounds of
AGREE II evaluation can be found in Additional file 1: Ap-
pendix 3). The guidance documents were given an overall
guideline assessment score of 5.3/7 (where 1 represents the
lowest quality, and 7 represents the highest quality).
Guidance statements
General principles (Table 2)
The SC noted that newborn screening in MPS IVA
would allow earlier diagnosis if/when available thus
leading to earlier intervention, which would likely
change the course of disease. As comprehensive re-
commendations for diagnosis of MPS IVA is out of
Table 2 General principles for the management of patients with MPS IVA
Statement Percentage consensus
All guidance statements are evidence Grade D (level 5 expert clinical opinion)
Diagnosis of MPS IVA during infancy is critical to optimise patient outcomes 98%
The first consultation should be conducted by a physician with experience of treating MPS as soon
as possible after diagnosis. This should include a full discussion of disease pathology, progression,
treatment options and management. Ongoing information should be provided to optimise patient
outcomes
97%
Patients and caregivers should receive ongoing psychosocial support from a social worker and/or
psychologist, and should be directed towards an MPS society or relevant patient organisation in
their country
94%
A comprehensive medical history and multi-system evaluation should be conducted within days of
diagnosis to set a baseline for ongoing assessments and evaluate the physical and neurological
manifestations of disease, functional ability and disease burden
88%
Ongoing and regular multi-system monitoring, and assessments are recommended to track the natural
history of MPS IVA, monitor the impact of treatment and assess the need for treatment interventions to
manage the symptoms of MPS IVA. These should be conducted at every clinic visit, annually or in some
cases as clinically indicated (for example pre- and post-operatively)
100%
Timely interventions are recommended where clinically indicated by monitoring, to help avoid irreversible
damage caused by the natural history of MPS IVA, and to manage the disease manifestations and maintain
long-term QoL
99%
A multidisciplinary team (MDT) of metabolic specialists, surgeons and allied healthcare professionals
(including, but not limited to: nurses, physiotherapists, occupational therapists, psychologists and audiologists)
is required to manage the diverse range of disease manifestations of MPS IVA
99%
Co-ordination of the entire MDT care team is required prior to any procedure to determine the need for
surgery, to discuss the benefits and risks of combining surgeries to minimise the need for multiple
anaesthetics and to decide the optimal order of procedures. The decision to combine surgeries should take
into consideration the surgical and intubation time, and complexity of procedures
93%
The risks and benefits of any intervention and the competing risks of other medical problems should be
assessed and discussed with patients, families and caregivers such that they can make an informed decision
on the appropriateness of the therapy/surgery
100%
Surgical procedures should be performed by (or under the guidance of) specialist surgeons and anaesthetists
with experience of MPS, in medical centres with intensive care units
99%
Management of pain should be a fundamental part of the care of patients with MPS IVA, with the aim of
improving QoL and maintaining mobility. Refer to general guidelines for pain management
100%
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scope of this guidance, more detailed discussions of
newborn screening can be found elsewhere [17]. General
guidelines for pain management in patients with MPS
have also been published elsewhere [26, 27].
Recommended routine monitoring and assessments (Table 3)
Disease-modifying interventions
ERT (elosulfase alfa) in patients with MPS IVA (Table 4)
Rationale and evidence base Elosulfase alfa [28] is a
recombinant form of the human lysosomal enzyme
GALNS, which is deficient in patients with MPS IVA
[29]. ERT with elosulfase alfa aims to transiently restore
GALNS activity, thereby preventing the accumulation of
KS and chondroitin-6-sulphate in lysosomal compart-
ments of cells, which is responsible for the clinical mani-
festations of MPS IVA. Elosulfase alfa is currently the
only disease-specific treatment that is licensed for pa-
tients with MPS IVA, having been validated in clinical
trials [30–32]. In a Phase III clinical trial, patients who
received intravenous elosulfase alfa at a dose of 2 mg/kg/
week experienced reductions in urinary levels of keratan
sulphate (a pharmacodynamic biomarker for the disease)
[30]. Elosulfase alfa has been shown to improve endur-
ance and exercise capacity (as measured by the 6MWT),
which may in part relate to improved respiratory func-
tion and oxygen utilization [30, 33–36]. A trend for im-
provement in performance of ADL was also observed in
a long-term extension study. The findings suggest that
long-term elosulfase alpha ERT is associated with partial
recovery of functional abilities, improving Morquio A
patients’ abilities to perform ADL [36]. The evidence for
the effect of elosulfase alfa on bone is currently limited
and further research is required.
Elosulfase alfa is well-tolerated [37] and results of a
randomized, double-blind, pilot study has shown that
treatment reduces pain in some patients with MPS IVA
[38]. The majority of adverse events in clinical trials
were infusion associated reactions (IARs), which are
defined as reactions occurring after initiation of infusion
until the end of the day following the infusion. Serious
IARs were observed in clinical trials and included ana-
phylaxis, hypersensitivity and vomiting [28]. As stated
on the US Prescribing Information for elosulfase alfa,
the most common symptoms of IARs (occurring in
≥10% of patients treated with elosulfase alfa and ≥ 5%
more when compared with placebo) were headache,
nausea, vomiting, pyrexia, chills and abdominal pain.
IARs were generally mild or moderate and the frequency
was higher during the first 12 weeks of treatment and
tended to occur less frequently with time [28, 39].
Early intervention with elosulfase alfa is associated
with a trend towards improvement in growth however
the data is currently limited [40]. Most data related to
the use of elosulfase alfa are from patients who initiated
ERT relatively later in their disease. The early initiation
of ERT will likely change the course of disease in
patients with MPS IVA; therefore, additional studies are
warranted to determine the long-term outcomes of
patients in whom elosulfase alfa treatment is adminis-
tered from an early age.
Considerations prior to starting ERT It is important
to evaluate the life-long impact of elosulfase alfa on an
individual basis, as the benefits of treatment may not be
consistent across all patients and there may be subpopu-
lations of patients where the risk-benefit and efficacy
versus cost effectiveness is less certain (e.g. less severe
phenotypes) [41]. The status of the patient, disease bur-
den, comorbidities and prognosis should be fully consid-
ered prior to initiation. The first dose of elosulfase alfa
should (where possible) be administered by a clinician
with experience of metabolic disorders and take place
within an infusion centre/hospital with facilities for ef-
fective management of allergic/anaphylactic reactions.
Home infusion may be considered where possible; this
decision should be made by the physician and patient.
Careful patient selection, good vascular access and a de-
tailed management plan for IARs and anaphylaxis are es-
sential for the success of this approach [42].
Consideration should be given to the need for a totally
implantable vascular access device (TIVAD) to facilitate
long-term venous access for frequent or continuous ad-
ministration of ERT; the patient and their families
should be made aware of the benefits and risks of using
such a device [43, 44]. Patients with acute febrile or re-
spiratory illness may be at increased risk of
life-threatening complications from hypersensitivity re-
actions; therefore, the clinical status of each patient
should be evaluated prior to the administration of
elosulfase alfa and if necessary, delay of treatment
should be considered.
Considerations for monitoring response Baseline and
follow-up assessments to measure treatment efficacy
should be performed before, and regularly after, initi-
ation of elosulfase alfa. These should include uGAG/KS
levels, endurance testing (preferably 6MWT), respiratory
function (if age compatible), growth, height and weight,
pain, ADL and QoL. Thorough examination of upper
and lower limb function (including active and passive
range of movement and nerve conduction studies)
should be performed to assess for evidence of cervical
cord compression. Assessment of medical history should
also be conducted to obtain as much information as pos-
sible. Stop criteria should be considered on an individual
basis where the burden of infusion outweighs the bene-
fits of treatment; however, at present this point is not
universally predictable. There is currently no published
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Table 3 Recommended routine monitoring and assessments in patients with MPS IVA
Statement Percentage consensus
All guidance statements are evidence Grade D (level 5 expert clinical opinion), unless otherwise stated
Physical examination
A physical examination should be performed during every visit to assess general health, growth, vital signs,
abdominal organ size, presence of hernia, neurologic function (including gait), ligamentous laxity, and
functions of the eyes, ears, heart and lungs
90%
Routine physical examination can also identify signs of potential respiratory problems, such as an enlarged
tongue or sniffing position
90%
Radiology
While X-rays are essential to identify the natural history of disease and response to treatment, efforts should
be made to minimise radiation exposure, and images should be requested only when clinically useful
85%
Hips: an anteroposterior (AP) pelvis radiograph should be performed at diagnosis and as clinically indicated
(based on physical examination or reports of pain) to quantify hip dysplasia or identify early signs of hip migration
88%
Lower limbs: in patients with clinical evidence of valgus deformity of the lower limbs, standing AP
radiographs of lower extremities should be performed prior to guided growth surgery
100%
Spine: standing or sitting plain radiography of the cervical and thoracolumbar spine to examine for spinal
deformities is recommended in patients with MPS IVA at diagnosis and every 2–3 years thereafter, or sooner
if clinically indicated
85%
Magnetic resonance imaging (MRI) of the whole spine (in neutral position) should be performed annually
in children with MPS IVA to assess for spinal cord injury. The frequency may be reduced for adult patients
with stable imaging who do not display symptomsa
84%
Flexion/extension MRI of cervical spine may be needed to identify changes in spinal canal and spinal cord 86%
MRI of the brain is recommended at diagnosis in patients with MPS IVA, and should be repeated as needed
in individuals with clinical suspicion of hydrocephalus
80%
MRI of the brain and spinal cord in patients with MPS IVA may require sedation or general anaesthesia,
depending on patient age and cooperation. General anaesthesia carries substantial risk for patients with MPS
95%
Flexion/extension computerised tomography (CT) of the craniocervical junction may be considered in patients
with MPS IVA if MRI is not available or if sedation is not possible
92%
The presence of specific radiological signs may indicate the need for surgical intervention to correct skeletal
deformities; however, there is insufficient evidence to support preventative surgery based on radiological findings
88%
Endurance
Choice of assessment depends on the patient’s physical and developmental ability 97%
Baseline assessment is the most important and ideally two values should be obtained as a minimum. Consistent
protocols should be used when performing repeat measurements to minimise variability
95%
Annual endurance testing using the 6-min walk test (6MWT) is recommended, as per the American Thoracic
Society guidelines [1, 45]
Evidence Grade: C (level 4 study and extrapolation from level 1 study) [8, 46]
87%
In patients with limited ambulation who are unable to perform the 6MWT, endurance should be assessed via
alternative methods such as an adapted timed 25-ft walk test (T25FW)
76%
Endurance testing is also recommended prior to initiation of ERT and annually thereafter as a measure of treatment
efficacy and to provide early evidence of possible neurologic or skeletal issues
87%
Growth
Assessment of growth should be performed at each clinic visit (ideally every 6 months) as part of a regular
physical examination and should include: standing height (sitting height if the patient is unable to stand), length
(supine position), weight, head circumference (≤3 years), Tanner pubertal stage (until maturity) [47]
95%
Height and weight should also be measured before initiation of ERT and at every clinic visit thereafter (ideally
every 6 months) to evaluate the impact of treatment [47]
95%
Urinary keratan sulphate (KS)/urinary glycosaminoglycan (uGAG) levels
Where available, tandem mass spectrometry may be used to assess levels of urinary keratan sulphate prior to
starting elosulfase alfa and every 6 months thereafter to determine the pharmacodynamic effects of ERT [48]
Evidence Grade: D (level 3/4 studies support the statement; [8, 49–54] however, one level 3 study [55] does not
support use of urinary keratan sulphate for monitoring the therapeutic effect of ERT)
94%
Total uGAG levels are often elevated in neonates and infants with MPS IVA and may overlap with normal values in
adults and some teenagers. However, if a specific keratan sulphate assay is not available, measurement of uGAG
levels using standard dye-binding methods may be useful. Preferably, measurements should be performed in the
same laboratory and assessed against age-related reference values
85%
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Table 3 Recommended routine monitoring and assessments in patients with MPS IVA (Continued)
Statement Percentage consensus
Cardiac function
Initial cardiac evaluation should be performed at the time of diagnosis and include assessment of vital signs
with measurement of oxygen saturation, right arm and leg blood pressure measurements, careful auscultation,
full transthoracic two-dimensional and Doppler echocardiogram, and 12-lead electrocardiogram (ECG)
100%
Longer ECG monitoring (prolonged Holter/event monitoring) may be considered in older patients, especially
if they have symptoms of black outs, unexpected falls or dizziness
96%
Follow-up in expert centres should be annually initially, but may be extended to every 2–3 years if there is no
evidence of cardiac abnormality
92%
Additional cardiac assessment, including a standard ECGb, should be performed prior to any surgical procedure
requiring general anaesthesia
92%
Neurological exam
A detailed neurological examination should be performed at every clinic visit (minimally every 6 months) and,
where possible, these should correlate with imaging studies of the spine to detect early spinal stenosis or
instability compromising the cervical cord. For patients without clinical or radiographic concern, annual
neurological examination may be sufficient [56]
87%
Standard MRI of the cervical spine should be performed to assess for presence of spinal cord compression.
In the absence of significant spinal cord compression, proceed with flexion/extension MRI to confirm the
presence of worsening spinal cord compression with motionc
78%
Respiratory function and sleep disorder
Evaluation of respiratory function by spirometry, including forced vital capacity (FVC) and maximum voluntary
ventilation (MVV), should be performed to assess changes in lung volume and obstruction in children over
5 years of age
97%
Respiratory function should be assessed annually until children stop growing, and every 2–3 years thereafter,
provided that respiratory symptoms remain unchanged. Additional testing should be performed if respiratory
symptoms change or if intercurrent illnesses occur
91%
Normative values are not available, therefore change in absolute volume from patient’s own baseline will be
the best indicator of deterioration or improvement
97%
Measurement of respiratory rate and arterial oxygen saturation before and after annual endurance testing is
recommended
86%
Evaluation of gas exchange and respiratory function is also recommended before any planned air travel, to
ensure safety during the flight
86%
To identify symptoms of sleep apnoead, patients should be asked to report presence of snoring and morning
headaches at every clinic visit
100%
An overnight sleep study (polysomnography) is recommended at diagnosis (if possible, and no later than
2 years of age), and every 3 years thereafter or when signs and symptoms of obstructive sleep apnoea (OSA)
are noted
94%
Ear-nose-throat (ENT)
ENT examination, including tympanometrye, should be conducted every 3–6 months during childhood and
every 6–12 months thereafter
91%
ENT examination in patients with MPS IVA should include visualisation of the upper respiratory tract to
determine diagnosis, management and assist in pre-operative planning. Endoscopic examinations should be
recorded and kept, to monitor disease progression
92%
Fibreoptic examination in patients with MPS IVA should be performed at diagnosis and at least annually thereafter,
or as clinically indicated. For those individuals who require general anaesthesia, ENT examination should be
performed during the pre-operative evaluation for other surgical procedures
83%
Upper airway CT, focused on airway anatomy preferably with reconstruction, may be useful to identify the area
of the abnormality and possible cause of obstruction in patients with MPS IVA with suspected obstruction or
malaciaf
92%
Age-adjusted audiometric assessment as a baseline objective hearing evaluation should be conducted at first
clinic visit and repeated annually to assess conductive and sensory-neural hearing loss
Evidence Grade: C (Grade 4 studies) [57, 58]
100%
If speech problems are determined during ENT examination, an assessment by a speech pathologist should
be conducted [59]
100%
Balance tests should be conducted if the patient has a history of balance problem 95%
Ophthalmological function
Age-appropriate evaluations by an ophthalmologist is recommended every 6 months if possible, or at least
annually [60]
90%
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evidence reporting the effects of discontinuation of ERT
in MPS IVA, and additional research is required.
Considerations for managing specific adverse events
of interest Due to the potential for hypersensitivity reac-
tions with elosulfase alfa, patients treated in the clinical
trial programme received antihistamine premedication,
with or without antipyretics, 30 to 60min prior to the
start of the infusion. This approach is broadly followed in
clinical practice but there is limited evidence for or against
the necessity of premedication. Patients should be closely
observed for signs of anaphylaxis during and after admin-
istration of elosulfase alfa and if severe hypersensitivity
reaction occurs, hospital admission is advised. Patients
with a with previous history of IARs, can be given add-
itional premedication, such as H2 receptor blockers or
montelukast sodium. Other risk factors may also include
history of severe allergic diathesis, status asthmaticus,
reactions to other infusion or biologic products, compro-
mised airway or pulmonary function and previous his-
tory of a significant pause between ERT treatment.
IARs are generally managed by reducing the rate of
administration or by temporarily interrupting the infu-
sion plus administration of additional antihistamines, an-
tipyretics, or for more severe reactions, corticosteroids
Table 3 Recommended routine monitoring and assessments in patients with MPS IVA (Continued)
Statement Percentage consensus
Ophthalmic assessment may include visual acuity, refraction, slit-lamp examination of cornea, funduscopic
evaluation including optic nerve, and measurement of intraocular pressure
100%
Scotopic and photopic electroretinogram may be performed in patients with clinical suspicion of retinopathy
or when considering corneal transplantation [60]
100%
Intraocular pressure monitoring and pachymetry may be considered prior to corneal transplant [60] 100%
Evaluation of oral health by dentist
Close monitoring of dental development (at least annually) is recommended to prevent caries and attrition, as is
monitoring of occlusion and chewing functions
100%
The need for subacute bacterial endocarditis (SBE) prophylaxis prior to dental procedures should be assessed by
a cardiologist
100%
Disease burden
Annual assessment of patient-reported outcomes is recommended for: pain severity, QoL (as assessed by
reproducible and age-appropriate questionnaires [e.g. EQ-5D-5 L]), fatigue), and activities of daily living (ADL;
as assessed by functional tests [6MWT/T25FW]), age-appropriate ADL questionnaires (e.g. MPS Health Assessment
Questionnaire [MPS HAQ]), and assessment of wheelchair/walking aid use [61]
97%
These assessments may have to be adapted both for language, culture, and individual physical limitations, as they
have not been validated in specific disorders
97%
Physical therapy
Regular assessments by a physical therapist (lower limb), occupational therapist (upper limb) and rehabilitation
medicine specialist should be conducted to assess limb function and provide support as needed
93%
The physical therapist could also assist in suggesting walking aids and other adaptations that may improve QoL 98%
Post-consensus comments by the SC to be taken into consideration:
aMagnetic resonance imaging (MRI) can also be used to assess for spinal cord compression. The frequency may be reduced for older patients with
stable imaging who do not display symptoms
bEchocardiogram (ECHO) should also be performed prior to any surgical procedure requiring general anaesthesia
cThis topic was discussed in detail with the neurosurgical and orthopaedic colleagues in the SC group. It was their expert clinical opinion that flexion/
extension MRI is not dangerous to perform within the hands of an experienced team. It is important that the range of motion (ROM), flexion and
extension of the patient is evaluated while they are awake immediately before anaesthesia. The ROM during anaesthesia should not exceed the ROM
as noted in the awake state, and should only be carried out after it is confirmed that there is no spinal cord compression. See Table 9 for guidance
statements on spinal surgeries including spinal cord decompression
dSigns and symptoms for sleep apnoea (a type of sleep disordered breathing (SDB)) can be divided into nocturnal and daytime symptoms. Nocturnal
symptoms include loud snoring, observed episodes of breathing cessation during sleep, abrupt awakenings accompanied by gasping or choking, and
awakening with a dry mouth or sore throat. Daytime symptoms include excessive daytime sleepiness, morning headaches, difficulty concentrating
during the day, personality and mood changes including depression or irritability, and high blood pressure. To identify presence of SDB, patients
should be asked to report snoring and other signs and symptoms of SDB at every clinic visit
eTympanometry is used to measure the volume of the ear canal/tympanic membrane movement and indirectly assess for fluid accumulation and
opening of pressure equalising tubes
fUpper airway CT may also be useful to identify the area of the abnormality and possible cause of obstruction in patients with MPS IVA with suspected
tracheo bronchomalacia
Table 4 Guidance statement for elosulfase alfa
Statement Percentage consensus
Initiation of long-term ERT with elosulfase alfa at a dose of 2.0 mg/kg/week through intravenous
infusion is recommended in all patients with MPS IVA as soon as possible after a confirmed diagnosis
Evidence Grade: B (level 2 or 3 studies)
79%
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(for a 12–18-h period prior to infusion). Due to the risk
of sleep apnoea in patients with MPS IVA, use of a
non-sedating antihistamine is recommended.
HSCT in patients with MPS IVA (Table 5)
Rationale and evidence base Evidence supporting the
use of HSCT in patients with MPS IVA is limited and
comprises a small number of case studies and a single
institution evaluation of ADL following surgical inter-
vention [40, 62–66]. Evidence of GALNS expression was
confirmed following transplantation, which showed the
potential for cross-correction of other tissues [40, 62–
66]. Improvements in height and skeletal dysplasia have
not been observed but this may be due to the transplant-
ation being performed in older patients [40, 62–66].
Due to increasing availability of well-matched donors,
improved supportive care and modification to transplant
regimens, the risks associated with transplantation have
declined in recent years; however, mortality rates still
vary between centres depending on experience, and ser-
ious risks, including death, remain. A recent study sug-
gests that peri-transplantation mortality has improved;
however, this data was from two of the most experienced
centres with MPS transplantation and involved other
subtypes of MPS [67].
Due to the lack of evidence related specifically to MPS
IVA, and the recognised risks of transplantation, HSCT
cannot be considered as a recommended therapy in
patients with MPS IVA. The strongest data for the use
of HSCT are for other types of MPS, namely MPS IH
(Hurler syndrome) [68]. Patients with MPS IH are
treated with HSCT due to the effectiveness of this
approach in treating the central nervous system (CNS)
manifestations of the disease, which are not improved by
ERT [69–73]. In MPS IH, the increased risk of HSCT
compared with ERT is considered justified. Given that
CNS disease is not prominent in patients with MPS
IVA, the risk–benefit profile for the use of HSCT in
these patients is less clear. There are reports that the
incidence of hydrocephalus and cervical stenosis is
decreased in MPS IH patients treated with HSCT as
compared to treatment with ERT [74]. As there are no
inherent cognitive manifestations in patients with MPS
IVA similar to those seen in patients with MPS IH, it is
unclear whether HSCT may be advantageous in patients
with MPS IVA and caution should be taken when
extrapolating evidence from other MPS types [11, 17, 75].
There is a need for more research to better understand
the long-term efficacy and safety of HSCT in patients with
MPS IVA, and for a well-designed comparative study
of HSCT and ERT in patients of similar age and
disease severity.
Interventions to support respiratory and sleep disorders
Continuous positive airway pressure (CPAP), non-
invasive positive pressure ventilation (NIPPV),
oxygen supplementation and hypercapnia monitoring
(Table 6)
Rationale and evidence base Respiratory complica-
tions are a major cause of morbidity and mortality in pa-
tients with MPS IVA and are often among the first
symptoms to appear [18, 19, 76]. Typical features of MPS
IVA include upper and lower airway obstruction and re-
strictive pulmonary disease which result from a variety of
anatomical and functional abnormalities. Upper airway
obstruction is attributable to cranial abnormalities, a short
neck and progressive deposition of GAGs in the tissues
surrounding the supraglottic upper respiratory tract, while
lower airway obstruction reflects GAG deposition in the
airway walls with resultant tracheal and bronchomalacia.
Lung volume and chest expansion are further limited by
short stature, chest wall deformities and abdominal
organomegaly. Clinical manifestations include recurrent
upper and lower respiratory tract infections, obstructive
sleep apnoea (OSA) and impaired exercise tolerance [18].
If respiratory complications are not diagnosed and treated
appropriately, respiratory failure can ensue, leading to
early death [14, 77]. There is evidence that long-term ERT
is associated with sustained improvements in respiratory
function in patients with MPS IVA [34]. In contrast, spe-
cific interventions beyond ERT are required to address
OSA and other forms of sleep disordered breathing (SDB).
CPAP prevents upper airway collapse during inspir-
ation and is the mainstay of treatment for OSA in the
general population with benefical effects on blood pres-
sure, cardiac events, mortality and QoL. [78, 79] A
comprehensive review of the evaluation and treatment op-
tions for SDB in MPS concludes that applying CPAP can
prevent functional airway collapse during inspiration when
asleep and may improve obstruction-related pulmonary
hypertension, heart failure and/or respiratory failure [80, 81].
Table 5 Guidance statement for HSCT
Statement Percentage consensus
Due to the lack of evidence, HSCT cannot be recommended for patients with MPS IVA and at this time is considered an
investigational procedure
Evidence Grade: D (level 3/4 studies with inconsistent risk/benefit results)
91%
Akyol et al. Orphanet Journal of Rare Diseases          (2019) 14:137 Page 11 of 25
An alternate form of therapy is required for patients that
demonstrate either persistent OSA despite CPAP or
hypoventilation during sleep. NIPPV provides an in-
creased pressure during the inspiratory phase of breathing
to augment ventilation. Although outcome data in MPS
are scarce, the effectiveness of this therapy has been dem-
onstrated in a broad range of diseases including neuro-
muscular and chest wall disorders; which are features that
are frequently noted in patients with MPS. Evidence sug-
gests that this approach results in an improvement in
QoL, functional capacity and respiratory failure [81–83].
Supplemental oxygen can be prescribed for individuals
that demonstrate persistent nocturnal oxygen desaturation
and for patients who do not tolerate therapy with CPAP
or NIPPV. Caution is required when prescribing oxygen
because of the known suppression of respiratory drive and
arousal from sleep with the potential for either worsening
pre-existing hypercapnia or inducing onset of hypercapnia
in susceptible patients.
Considerations for intervention SDB can be managed
by application of CPAP, which delivers air at an elevated
pressure via a mask that fits around the nose and/or
mouth; however, consideration should be given to facial
abnormalities that can make mask-fitting difficult. Patients
should be monitored to ensure they do not develop sus-
tained hypoventilation. To prevent pneumonia, vaccina-
tions against respiratory pathogens causing influenza and
pneumococcus infections should be recommended.
Anaesthesia and surgical interventions
Use of anaesthesia in patients with MPS IVA (Table 7)
Rationale and evidence base Patients with MPS IVA
will likely require anaesthesia for multiple surgical inter-
ventions and investigations during the management of
their disease [84, 85] but are considered high-risk due to
potential difficulties with mask ventilation and endo-
tracheal intubation. Other risk factors include: the pres-
ence of narrow airways from adeno-tonsillar hypertrophy
and deformity of the lower airways, odontoid peg hypopla-
sia causing potential instability of the cervical spine, and
other skeletal abnormalities causing thoracic deformity
and pulmonary disposition. In addition, cardiovascular
and neurological impairment may also be present [86–88].
Adverse events (including fatalities and paralysis) oc-
curring during anaesthesia have been reported in the
literature [89–91]. Intubation and extubation can be
challenging in patients with MPS IVA due to several
factors including: restricted mouth opening; short neck
length; limited range of motion (ROM) and upper airway
obstruction, which is often caused by hypertrophied ton-
sillar/adenoidal tissue, a large tongue with micrognathia,
subglottic narrowing, and atlanto-axial instability due to
odontoid hypoplasia and ligamentous laxity [77, 86, 89,
92–97]. Some patients also experience tracheal obstruc-
tion, which in the presence of coexisting upper airway
obstruction commonly remains unrecognised and can
increase the risk of death during anaesthesia [89, 96].
Retrospective evaluation from 83 intubations of 108
anaesthetics (in 28 patients) demonstrated difficulties in
intubation following cervical fusion [89]. Airway abnor-
malities including tortuous appearance of the trachea
and bronchi as a result of the abnormalities in the hya-
line cartilage and deposits of glycosaminoglycans were
observed, suggesting that MPS IVA results in abnorma-
lities of both upper and large airways [89].
Management of the airway will require care to
maintain neutrality of the cervical spine and may
necessitate the use of videolaryngoscopy or fibreoptic
techniques. Although hypothetical, poor perfusion
related to arterial narrowing and reduced foramina di-
ameters secondary to dysostosis should be anticipated
by an anaesthetist, appropriately monitored with
arterial lines, and supported in near-normal range
during procedures.
Although epidural anaesthesia has been performed suc-
cessfully in patients with MPS IVA [89], it is not currently
recommended due to observations of spinal cord infarc-
tion following lower extremity surgeries in which patients
received an epidural for post-operative pain management
[91, 98, 99]. Although data on peripheral nerve block are
lacking, this approach may be considered during the care
Table 6 Guidance statements for CPAP, NIPPV, oxygen supplementation and hypercapnia monitoring
Statement Percentage consensus
CPAP therapy is recommended for patients with MPS IVA who display the presence of obstructive
sleep apnoea (OSA) that persists after tonsillectomy and/or adenoidectomy
Evidence Grade: D (limited published evidence)
97%
NIPPV therapy is recommended for patients with MPS IVA who display nocturnal hypoventilation
and are unresponsive to CPAP, or display daytime hypoventilation with increased PaCO2 and/or
serum HCO3 levels
Evidence Grade: D (level 5 expert clinical opinion)
91%
Oxygen supplementation during sleep is recommended for patients with MPS IVA who exhibit
sleep apnoea with nocturnal hypoxemia, and who do not tolerate CPAP or NIPPV masks
Evidence Grade: D (level 5 expert clinical opinion)
77%
Patients with MPS IVA should be monitored for development of hypercapnia after starting oxygen
therapy using measurement of PaCO2 and/or serum HCO3
Evidence Grade: D (level 5 expert clinical opinion)
97%
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of patients with MPS IVA. The use of ultrasound technol-
ogy can also aid successful nerve block. Intraoperative
neurophysiological monitoring is recommended to pre-
vent significant complications in this high-risk population;
however, availability is extremely variable.
Considerations for use of anaesthesia Due to the
risk of upper airway obstruction, pre-operative seda-
tive premedication may be used with caution and only
with appropriate monitoring. Assessment of upper and
lower airway anatomy (for example, a pre-operative flexible
nasopharyngolaryngoscopy and three-dimensional CT scan
where feasible), cardiac function, and potential cervical
spine instability should be performed prior to any pro-
cedure that requires sedation or anaesthesia. MRI scans
of the spine in a neutral position or patient-initiated
flexion/extension X-ray of the spine can be performed
to assess the risk of spinal cord compression and in-
stability (flexion extension X-ray measures instability
only). Flexion/extension imaging is important to evalu-
ate for cervical spine instability prior to anaesthesia.
The frequency of imaging depends on both the patient’s
age and clinical condition. Owing to potential unstable
cervical and thoracic spinal regions, it is critical to
maintain a neutral neck position during all surgeries
(including intubation and extubation) to avoid spinal
cord injury (which can lead to paralysis), sensory injury
with dysesthesia pain and/or loss of proprioception.
The anaesthetist should use techniques that allow a
neutral neck position to be maintained, including use
of a laryngeal mask airway for shorter procedures, or
intubation with a video laryngoscope or fibreoptic
scope. Use of a seated position [99] can be considered
and there should be a range of options available to se-
cure the airway and support ventilation. If possible, in a
very difficult airway scenario, intubation may be com-
pleted while patients are awake, and if the patient is
anaesthetised, the use of paralytic agents should be
avoided such that spontaneous breathing is maintained
until intubation is completed successfully. Displacing
the tongue anteriorly prior to intubation by manual re-
traction using a ring forceps or a piece of gauze may
help to access the larynx in children with MPS IVA
[89]. A smaller endotracheal tube should be available
and is usually necessary to avoid intraoperative swelling
Table 7 Guidance statements for anaesthesia
Statement Percentage consensus
Pre-, intra- and post-operative care (until extubation is complete) for all procedures requiring
general anaesthesia, conscious or deep sedation, should be supervised by an anaesthetist with
experience in treating patients with MPS and/or complex airway management. In addition,
the anaesthetist should have access to Intensive Care support and be surrounded by an
experienced team capable of performing emergency tracheotomy if required
Evidence Grade: C (consistent level 4 studies)
98%
A full assessment of the risks and benefits should take place with the patient and family prior
to any procedure. All pre-operative information should be made available to allow decision making
Evidence Grade: C (consistent level 4 studies)
100%
ENT respiratory, cardiac, and radiological assessment should be performed prior to any procedure
requiring anaesthesia
Evidence Grade: C (consistent level 4 studies)
93%
It is critical to maintain a neutral neck position during all surgeries, and during intubation and
extubation to avoid paralysisa. Strongly recommend the use of techniques that allow maintenance
of the neutral neck position, including use of laryngeal mask airway (LMA) for shorter procedures,
or intubation with a video laryngoscope or fibreoptic intubation
Evidence Grade: C (consistent level 4 studies)
87%
Pre-operative and intra-operative measures to avoid hypotension should be adopted during all
surgical procedures in patients with MPS IVA to maintain spinal cord perfusion and therefore
protect spinal cord function
Evidence Grade: D (limited published evidence)
98%
Intra-operative neurophysiological monitoring (including somatosensory evoked potential [SSEP],
electromyography [EMG] and motor evoked potentials [MEP]) is strongly recommended during all
spinal surgeries and other potentially lengthy or complicated procedures, including those that
require manipulation of the head and neck
Evidence Grade: D (limited published evidence)
94%
For other surgeries and procedures, neurophysiologic monitoring should be considered based on
pre-existing risk for spinal cord compression and instability, need for spine manipulation, possibility
of hemodynamic changes and blood loss, or extended length of time
Evidence Grade: D (limited published evidence)
94%
Intrathecal and epidural techniques are high-risk in patients with MPS IVA and should be avoided wherever possible
Evidence Grade: D (limited published evidence)
83%
Post-consensus comments by the SC to be taken into consideration:
aIt is critical to maintain a neutral neck position to minimise the risk of any spinal cord injury
Akyol et al. Orphanet Journal of Rare Diseases          (2019) 14:137 Page 13 of 25
of the airway and enable successful extubation. Where
possible, patients should be extubated in the operating
room and asked to demonstrate movement of the lower
extremities. If safe intubation cannot be achieved,
tracheostomy may be considered electively prior to pro-
longed surgery, or to facilitate post-operative care.
Mean arterial pressure should be maintained to maxi-
mise perfusion of the spinal cord and reduce the risk of
spinal cord injury. Intensive care management is often
not required but may be necessary for complicated or
prolonged procedures requiring post-operative ventila-
tion or peri-operative tracheostomy. If ventilation is
performed through an endotracheal tube, it is best to
aim for early extubation to minimise swelling of the air-
ways. When clinically indicated, maintenance of intub-
ation overnight following the procedure can be
considered to allow resolution of airway swelling. Extu-
bation should be performed by an experienced anaesthe-
tist capable of inspecting the airway before extubation
and, if necessary, performing reintubation. Wherever pos-
sible, alternative techniques (e.g. peripheral nerve block
under light sedation) should be considered to avoid gen-
eral anaesthesia and associated risks. However, the sur-
gical team should always be prepared to perform
general anaesthesia if required.
Considerations after surgery To reduce airway
oedema, intraoperative prophylaxis with steroids is the
standard treatment. The use of post-operative treatment
steroid prophylaxis may be required in some patients for
24 h following surgery. Standard treatment for patients
with upper airway obstruction should be available includ-
ing NIPPV, CPAP and continuous monitoring of respira-
tory and cardiac function. Intensive care management is
not mandatory for all patients, but when necessary, should
be maintained for 24–48 h post-surgery because of the po-
tential complications of oral secretions, thoracic cage stiff-
ness, heart and lung failure, apnoea, laryngospasm,
bronchospasm, cyanosis and respiratory failure.
Limb surgeries in patients with MPS IVA (Table 8)
Rationale and evidence base Patients with MPS IVA
have progressive musculoskeletal involvement; therefore,
multiple orthopaedic interventions are usually required
to prevent deformity, improve physical function and re-
duce pain [100, 101]. Typical features of MPS IVA that
do not occur in other types of MPS include joint hyper-
mobility and deformity in the wrists, which lead to
floppy wrists with weak grip and loss of fine motor skills.
Patients with MPS IVA have subluxation of the hip
joints and joint instability in the knees which can exacer-
bate genu valgum, patella dislocation and gait abnormal-
ities [14–16, 102]. Almost all patients with MPS IVA
develop genu valgum to an extent which is serious enough
to require surgery [101, 103]. A review of the literature for
outcomes of orthopaedic surgery suggest that correction
of genu valgum by hemi-epiphysiodesis may improve
QoL and function including improved walking dis-
tance (as measured by 6MWT); however, patients re-
main significantly impaired when compared to healthy
individuals [104, 105]. A case report of knee replacements
in two patients with MPS IVA also suggests that correc-
tion of genu valgum improves mechanical axis, mobility,
ADL and QoL [106]. While there is more evidence avail-
able for correction of genu valgum, data for other limb
surgeries are limited [104]. Evidence from case reports
supports the use of hip reconstruction as early as possible
(before the age of 10 years) to minimise progression of
subluxation and hip dysplasia and to improve out-
comes, reduce pain and facilitate hip replacement fol-
lowing surgical intervention. The expert SC
commented that improved function has been observed
following hip surgery; however, the majority of pub-
lished literature suggest that the outcomes of hip
surgery are judged largely on radiographic appearance
with little correlation with function. Assessment of
pelvic radiographs showed no correlation between
6MWT distance and degree of hip migration, and pa-
tients with hip migration greater than 40% had no in-
creased probability of being wheelchair-bound [105].
Overall, the expert opinion of the SC group is that pa-
tients are more mobile following hip surgery; however, the
literature is sparse and further data are required to sup-
port these observations.
Patient selection for intervention Before orthopaedic
intervention in patients with MPS IVA, morbidity and mor-
tality risks, pain level, optimal timing, and patient
Table 8 Guidance statements for hip reconstruction, hip replacement and growth modulation surgeries
Statement Percentage consensus
Hip reconstruction can be considered in paediatric patients with MPS IVA who exhibit hip pain,
reduced walking and endurance related to hip disease, as well as abnormal radiographic findings
Evidence Grade: D (limited published evidence)
86%
Hip replacement can be considered in adult patients with MPS IVA who exhibit hip pain, reduced
walking and endurance related to hip disease, as well as abnormal radiographic findings
Evidence Grade: D (limited published evidence)
100%
Growth modulation surgery is recommended for all patients with MPS IVA who have evidence of genu
valgum and should be performed as early as possible during the period of growth
Evidence Grade: D (limited published evidence)
77%
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preference should be considered on a case-by-case basis.
The need for hip surgery can be determined by presence of
hip pain, reduced walking endurance and abnormal radio-
graphic findings indicating hip dysplasia or lower limb
alignment. Growth modulation surgery should be initiated
as soon as the deformity is observed, or if the tibial-femoral
angle is greater than 15 degrees. For optimal results, it
should be performed early during the period of growth
due to the deceleration in growth that occurs as the skel-
eton matures, [100] however expert clinical opinion varies
regarding the ideal age to perform the surgery. The
period following the commencements of ERT may also be
a good time to perform growth modulation surgery.
Hemi-epiphysiodesis is indicated within the first decade of
life, after this point osteotomy should be considered.
Currently there is no hand surgical intervention that
can be recommended to improve the weakness of the grip
but maintain vital flexibility for transfer and adequate
ADL. External custom-made splints can be worn to help
with certain tasks e.g. heavy lifting. Occupational thera-
pists are vital to help with ADL including providing
gadgets to perform necessary tasks. Patients with weak
grip can learn to adapt to master necessary ADL.
Considerations for pre- and post-surgical monitor-
ing and assessment The primary goal of limb surgery is
not to improve or restore joint ROM, but to reduce pain
or improve mobility. Goniometer measurement per-
formed by a physiotherapist/occupational therapist/
rheumatologist may be useful, but this may not be avail-
able in all centres. Post-surgery physical assessments
should be performed regularly, as patients with MPS IVA
may require repeated surgeries/interventions. Patients
who have undergone hemi-epiphysiodesis around the
knee at one level (tibial or femoral only) and who show
evidence of progression of genu valgum during follow-up
should be considered for a second growth modulation
procedure on the unoperated level (tibial or femoral).
Considerations for surgery All surgeries should be su-
pervised by an anaesthetist with experience in treating
MPS and/or complex airway management (refer to the
anaesthetics recommendations). Limb surgeries should
be performed by an orthopaedic surgeon with a basic
understanding of MPS including: clinical presentation,
musculoskeletal abnormalities and radiographic findings.
An overnight hospital stay is recommended following
hip surgery to allow access to intensive care, should this
be needed, although this may not be necessary for more
minor surgeries, such as hemi-epiphysiodesis. Long-term
intensive physical therapy is recommended post-surgery to
enhance recovery.
Spinal surgeries in patients with MPS IVA (Table 9)
Rationale and evidence base Spinal involvement is a
major cause of morbidity and mortality in patients with
MPS IVA. Early diagnosis and timely treatment of spinal
stenosis/instability is critical in preventing or arresting
neurological deterioration and loss of function. Spinal
involvement in patients with MPS IVA occurs at three
locations. Cervical involvement, particularly instability
and compression at C1–C2, is very common and predis-
poses patients to myelopathy, paralysis and sudden death
[11]. Upper cervical and craniocervical pathology is
commonly seen in patients with MPS IVA; dens hypo-
plasia in combination with ligamentous laxity can lead
to atlantoaxial instability, and subsequently, to spinal
canal stenosis and spinal cord compression [107]. Al-
though craniocervical junction instability plays a
major role in cervical cord pathology in patients
with MPS IVA, a retrospective analysis of 28 patients
suggests that decompression surgery without
occipito-cervical stabilisation may yield good postoperative
results [108]. Spinal cord compression can also occur at
the cervicothoracic level, and is often missed [56]. Spinal
cord compression due to kyphotic deformity at the thora-
columbar level is not as common but can lead to paraple-
gia [102, 109, 110]. Evidence from small case studies in
patients with MPS indicates that thoracolumbar spine
fusion was associated with good outcomes [111, 112].
ERT and HSCT are of a limited use in preventing the
development of skeletal deformities in patients with MPS
Table 9 Guidance statements for decompression of the spinal cord, spinal stabilisation and thoracolumbar kyphoscoliosis
Statement Percentage consensus
Decompression of the spinal cord is recommended in patients with MPS IVA who have evidence
of spinal cord compression based on clinical and radiographic findingsa
Evidence Grade: C (level 3/4 studies)
97%
Spinal stabilisation of the craniocervical junction with either cervical fusion or occipital-cervical
fusion is recommended in patients with MPS IVA who have evidence of significant instability
Evidence Grade: D (limited published evidence)
97%
Correction of thoracolumbar kyphoscoliosis is recommended in patients with MPS IVA who present
with progressive radiographic deformity, intractable pain and neurological deterioration
Evidence Grade: C (level 3/4 studies)
100%
Post-consensus comments by the SC to be taken into consideration:
aThe SC would like to clarify that neuroimaging is a required radiologic procedure to define compression. MRI is best to image the brain and spinal cord for this
indication. Decompression of the spinal cord is recommended in patients with MPS IVA who have evidence of spinal cord compression and risk of injury based
on clinical and neuroimaging findings
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IVA, therefore, early surgical intervention is important to
manage neurological manifestations. Spinal instability can
exacerbate spinal cord compression; therefore, a com-
bination of multiple surgeries may be required. Based on
expert experience and a few case series/studies, the
consensus is that short-term post-operative outcomes
are generally favourable, with high fusion rates, as well
as varying degrees of neurological improvement, im-
proved clinical outcomes, and reduction in long-term
morbidity [113].
Patient selection for intervention Indications for sur-
gery include cervical spinal cord compression as deter-
mined by clinical symptoms (including weakness,
numbness, paraesthesia and gait difficulty) and upper
motor neuron signs or radiographic and MRI findings
(including plain radiographic findings suggestive of
stenosis and instability and MRI findings of extradural
stenosis, cord compression, myelomalacia and
instability).
Consideration should be made for timing of surgery in
relation to cardiac valve replacement, as the latter
procedure could subsequently commit the patient to
lifetime anticoagulation therapy.
Considerations for surgery Spinal surgeries should be
performed by a neurosurgeon and/or spinal surgeon
with a basic understanding of MPS and of the clinical
presentation, musculoskeletal abnormalities and radio-
graphic findings associated with this group of disorders
[99].
Ophthalmic surgery in patients with MPS IVA (Table 10)
Rationale and evidence base The most notable oph-
thalmic manifestations in patients with MPS IVA are
pseudoexophthalmos secondary to shallow orbits, cor-
neal clouding retinopathy and optic neuropathy [114].
Although corneal clouding in patients with MPS IVA is
generally mild, the opacification tends to worsen with
age, and severe clouding has been reported in some
older patients [115]. Clear corneal grafts can be achieved
for patients with MPS IVA who have corneal clouding;
these can improve visual acuity in some patients [116].
There were no reported cases of rejection or recurrence
in studies of corneal transplantation in patients with
MPS IVA [116, 117]. However, it should be noted that
these studies were performed in adults and rejection
rates tend to be higher in children.
Patient selection for intervention Corneal transplant-
ation should only be considered once retinopathy and
optic nerve abnormalities have been assessed (by electro-
retinography and visual evoked potentials) and excluded
as a significant contributing factor to the loss of vision.
The choice of surgical technique for corneal transplant-
ation (deep anterior lamellar keratoplasty [DALK] versus
penetrating keratoplasty [PK]) should be made on a
case-by-case basis. There is some evidence extrapolated
from the general population to suggest that rejection is
more likely to occur following PK than DALK [115, 117,
118], therefore, DALK should be considered in patients
with MPS IVA.
Considerations for intervention (e.g. if surgery)
Monitored anaesthesia with appropriate sedation, inclu-
ding use of nasal CPAP/NIPPV, may be used when per-
forming eye surgery in patients with MPS IVA. Long-term
topical treatment is required following corneal transplant-
ation, as is regular, long-term (annual) ophthalmic assess-
ment to determine the health of the corneal graft and to
check for recurrence of corneal deposits and astigmatism
control. Signs of rejection require prompt ophthalmic
assessment to prevent graft failure. Follow-up is required
to monitor for optic neuropathy arising due to raised
intracranial pressure. Symptoms can include reduction in
visual acuity, abnormal pupil reactions, new onset of
visual field defects or optic nerve swelling (or, more
commonly optic atrophy).
Cardio-thoracic surgery in patients with MPS IVA
(Table 11)
Rationale and evidence base Cardiac involvement is
most commonly reported in patients with MPS I, II and
VI [119]. However, results of an observational study in
54 adolescent and young adult patients with MPS IVA
identified age-related aortic root dilation, thickened
left-sided cardiac valves, increased heart rate and im-
paired diastolic filling pattern [20]. Valve dysfunction
was present in 5/54 patients, with aortic regurgitation
being the most common [20].
Patient selection for intervention Performance and
interpretation of echocardiography should be completed
by physician’s familiar with expected pathological
findings in patients with MPS IVA [119]. Valve replace-
ment decisions should be based on current European
Society of Cardiology (ESC), European Association for
Table 10 Guidance statement for corneal transplantation
Statement Percentage consensus
While significant corneal clouding is rare in patients with MPS IVA, corneal transplantation
can be considered for patients with significant visual loss attributed to corneal
opacification
95%
Evidence Grade: D (limited published evidence)
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Cardio-Thoratic Surgery (EACTS) and American Heart
Association (AHA) guidelines [120, 121] in conjunction
with assessment of existing co-morbidities, operative risk
and rehabilitation potential. Trans-catheter aortic valve re-
placement may be feasible for some MPS IVA patients. The
Ross procedure is contraindicated in patients with systemic
valvular disease [122] and should not be employed in pa-
tients with MPS IVA. Small valve annulus may preclude
valve replacement with currently existing mechanical and
bio-prosthetic cardiac valves. Aortic root replacement has
not been reported in patients with MPS IVA.
Consideration for surgery Cardiac surgery in patients
with MPS IVA should be performed in a centre of excel-
lence with a team experienced in treating both MPS and
high-risk valve replacement. When possible, an anaes-
thetic specialist should assist the cardiac anaesthesia
team during pre-operative assessment to formulate the
MPS-related anaesthesia care. Airway care, including
the need for tracheostomy, should be assessed on a
case-by-case basis. The anaesthesia principles of care
(outlined in the anaesthetics recommendations)
should be followed during the care of patients with
MPS IVA for cardiac procedures.
Ear, nose and throat surgery in patients with MPS
IVA (Table 12)
Rationale and evidence base ENT manifestations
are common in patients with MPS IVA. These often
involve hearing disorders, serous otitis media and de-
formities of the ossicles, which can have a significant
impact on patient functional status and QoL [123].
Mixed hearing loss is more common than either con-
ductive or sensorineural hearing loss alone [124]. Evi-
dence from two non-randomised follow-up studies
indicates that ENT surgery (e.g. adenotonsillectomy,
adenoidectomy with insertion of middle ear ventila-
tion tubes, tonsillectomy, tracheotomy and exeresis of
vocal cord polyps) reduces hypoacusia, otitis media,
upper respiratory tract infections, occurrence of OSA,
and the need for Type B tympanograms. QoL was
also reported to be improved in some patients [123,
125]. The results of other non-randomised follow-up
studies show that tonsillectomy and/or adenoidectomy
improves OSA in the majority of MPS patients, how-
ever, the recurrence rate after adenoidectomy is high
[125]. Risks include development of secondary haem-
orrhage following tonsillectomy and/or adenoidect-
omy. In addition, difficult intubations are common in
these patients and can be fatal [125, 126]. Advanced
surgical options such as uvulopalatopharyngoplasty,
mandibular advancement surgery or tongue reduction
are currently experimental. While one member of the
SC had experience, there are currently insufficient
data and experience to make recommendations about
the use of these invasive procedures in patients with
MPS IVA.
Considerations for surgery Vaccinations against re-
spiratory pathogens causing influenza and pneumo-
coccus infections are recommended to prevent
pneumonia. Insertion of ventilation tubes should be
performed according to guidelines for the general
paediatric population [127]. Before performing
Table 11 Guidance statement for cardiac valve replacement
Statement Percentage consensus
Cardiac (aortic, mitral) valve replacement should be considered in patients with
MPS IVA who display symptomatic and severe valve stenosis or regurgitationa
Evidence Grade: C (level 4 studies)
95%
Post-consensus comments by the SC to be taken into consideration:
aThe Ross procedure should not be employed in patients with MPS IVA [57]
Table 12 Guidance statements for tonsillectomy and/or adenoidectomy, tracheostomy and insertion of ventilation tubes
Statement Percentage consensus
Tonsillectomy and/or adenoidectomy is recommended for patients with MPS IVA who display
recurrent otitis media, snoring and/or OSA as early as possible following diagnosis without
waiting for disease progression
Evidence Grade: C (level 2, 3 and 4 studies)
94%
Insertion of ventilation tubes is recommended for patients with MPS IVA with otitis media with
effusion and/or recurrent otitis media to maintain hearing and/or prevent recurrent acute otitis media
Evidence Grade: D (limited published evidence)
100%
Tracheostomy is recommended in patients with MPS IVA who do not respond to any of the
treatment modalities mentioned above
Evidence Grade: D (limited published evidence)
77%
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tonsillectomy, children with MPS IVA should be re-
ferred by the clinician for polysomnography to evalu-
ate for SDB [128]. Patients who have had
tonsillectomy and/or adenotonsillectomy should be
observed as in-patients and may need to remain in
hospital preferably in intensive care in the early
post-operative period to monitor airway patency. They
may need to remain hospitalised for additional days
to allow close monitoring for possible haemorrhage
and other complications. Patients with ventilation
tubes should be assessed every 3 months, and
post-operative audiologic examination should be per-
formed if there is no improvement in hearing. The
anaesthesia plan should be discussed jointly between
the otolaryngologist and anaesthesia care team. Pre-
cautions to prevent spinal cord compression should
be taken during surgical procedures.
Discussion
MPS IVA and VI are rare, heterogeneous and progressive
disorders that are associated with severe morbidity and re-
duced mortality. Although previously published guidance
is available for the management of MPS IVA/VI [11, 17,
40, 75, 129, 130], these were largely based on clinical
opinion among a relatively small group of experts and
therefore the methodology used to generate this guidance
has come under increased scrutiny. This programme used
a robust, systematic approach to develop consensus-based
guidance among a broad group of experts to improve
the holistic care of patients with MPS IVA/VI (the
results for MPS VI can be found in the companion
article (Recommendations for the management of MPS VI:
systematic evidence- and consensus-based guidance).
Developing guidance in rare diseases, such as MPS
IVA/VI, is often challenging. The low patient numbers
often mean that there is a paucity of large-scale ran-
domised trials and systematic reviews available in the
literature. As such there is a need for robust consensus-
based guidance to bridge the gap between the relatively
small number of clinicians with experience in treating
patients with MPS IVA/VI, and the broader community
of healthcare professionals involved in the management
of these patients. However, with consideration of the
challenges including lack of evidence and limited re-
sources, guidelines remain critical for driving consistency
and quality of care in rare diseases [131].
Strengths and limitations of the programme
Management of MPS IVA/VI requires a coordinated
multidisciplinary approach; therefore, it was important
that this guidance covered a broad range of topics. How-
ever, as is common with rare diseases, high-quality
evidence was not available for all the medical and surgi-
cal interventions covered in this guidance. As a result, it
was necessary to draw on the expert clinical experience
of the SC and broader modified-Delphi respondents to
develop consensus-led guidance. Key strengths of this
programme included the robust methodology used to
identify and coordinate experts from a wide range of
specialties and geographic spread, the systematic review
of available literature and consensus on a broad range of
guidance statements. This was achieved through a sys-
tematic approach to select the programme Co-Chairs
and identify appropriately-qualified respondents for the
modified-Delphi voting. Additionally, the inclusion of three
PAG representatives as part of the SC group and interview
analysis from six global PAGs, ensured that the patient per-
spective was reflected in the guidance. The comprehensive
systematic literature review ensured that the resulting guid-
ance was developed on the current evidence base and the
use of a blinded modified-Delphi voting process to gain
consensus ensured that the guidance reflected the views of
a wide range of specialists with specific experience in man-
aging the complex needs of patients with MPS IVA/VI. The
methodological rigour and transparency employed within
the development of the guidance was further demonstrated
through the review of the manuscripts against the validated
AGREE II instrument (www.agreetrust.org). Three inde-
pendent reviewers assessed the manuscripts and suggested
amendments were addressed where possible; a subsequent
second round of review was conducted by all reviewers.
The manuscripts were given an overall guideline assess-
ment score of 5.3/7 (where 1 represents the lowest quality,
and 7 represents the highest quality).
Limitations of the programme reflect other chal-
lenges of developing guidance in rare diseases includ-
ing achieving multi-sponsor funding. While this
programme was sponsored by a single funder, mea-
sures were taken to ensure this did not influence the
final guidance statements (outlined in the methods and
process section). Due to the limited funding available
within the field of rare diseases, additional sponsorship for
this programme was unavailable. However, the Steering
Committee group encourages future multi-sponsored con-
sensus programmes for updates to this guidance and in
other MPS types/rare diseases.
Access to relatively expensive therapies such as ERT,
as well as access to other medical and surgical care can
be challenging for exceptionally rare diseases. Patients’
access to treatment in rare diseases varies geographic-
ally based upon national reimbursement schemes. It is
important that inclusion/exclusion criteria for treat-
ment is not arbitrary and does not discriminate against
slowly progressing patients, where a health gain cannot
often be confirmed over a short period of time [35,
132]. Consideration should also be given to the unique
challenges of rare diseases, which are often underser-
viced by investment, with relatively high costs, which
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may not be captured by conventional cost-benefit ana-
lyses. Given that price and health systems vary across
the world, and these guidelines are intended for global
use, it was difficult to apply one cost analysis to these
guidelines, therefore consideration of cost analyses was
not included in this process.
Facilitators and barriers to the implementation of the
guidance
The PAG consultations provided patient and caregiver
insight into the barriers and facilitators to the appli-
cation of this guidance across numerous healthcare
systems and geographies, and the results were reviewed
and further considered from a clinical perspective by the
SC group. It was considered that patients and their
families are likely to drive the dissemination and appli-
cation of this guidance among healthcare professionals
and that this can be supported by making the guidance
widely available, for example, via the websites of MPS
societies. To address knowledge barriers for healthcare
professionals, the SC recommends that a number of
materials should be developed including: case studies to
support implementation of the guidance statements (e.g.
using local experience that demonstrates the benefit of
early diagnosis and treatment); a guidance document to
provide advice on specific questions that should be
asked and data that should be collected at each clinic
visit; and guidance and training on how to develop an
emergency plan for patients as it is not always possible
to get an MDT together quickly. The SC also re-
commended the development of a frequently asked ques-
tions (FAQ) document for use by PAGs and patient
organisations. Following publication of the guidance, mem-
bers from the SC group will partner with organisations
such as PAGs and pharmaceutical companies to further
understand the facilitators and barriers to the application
of the guidance, including cost considerations. Subsequent
support programmes will then be developed to deliver the
recommended actions within the guidance.
The SC highlighted the benefits that existing industry-
sponsored MPS registries play in supporting data collec-
tion and discussed how these may provide important data
on outcomes of medical and surgical interventions. One
example is the elosulfase alfa NICE-managed access agree-
ment in England, which aimed to collect data on the
long-term efficacy and safety of elosulfase alfa as well as
prevalence and effectiveness of other treatment paradigms
[133]. The SC group discussed the value of the continu-
ation of such registries and suggested that these could be
run by a range of stakeholders beyond industry. The SC
recommends that patients should be empowered to take
an active role in their care with emphasis being placed on
the increasing importance of their role in generating data
(e.g. patient-reported outcome measurements [PROMs]).
The development of international, regional multidisciplin-
ary centres could be used to optimise monitoring, treat-
ment and data collection. Further, improved recording of
data (particularly those relating to HSCT) through partici-
pation in international registries will help to address evi-
dence gaps, assist treatment decisions and improve
outcomes for patients with MPS IVA/VI.
Future directions
Improvements in symptom management and the intro-
duction of ERT for MPS IVA/VI may create new chal-
lenges for the future. As life expectancy increases, the
challenge will be to manage a growing population of
adult patients who may require multiple surgeries
throughout their lifetime and therefore the associated
anaesthetic risks will gain greater importance. Similarly,
the introduction of newborn screening will facilitate
early treatment and has the potential to change the nat-
ural history of MPS IVA/VI. MPS I has already been
added by the Secretary of the Department of Health and
Human Services to the list of routine recommended
conditions to be screened in the USA, and the inclusion
of other MPS types should follow as testing technology
becomes more established and the benefits of early
diagnosis and treatment become clearer. Biochemical
enzyme assays continue to be important for differential
diagnosis of MPS types and several assays for enzymes
relevant to MPS IVA/VI have been described [134–138].
A novel urine assay has been developed that allows diag-
nosis of 10 subtypes of MPS in a single test by measuring
oligosaccharides with non-reducing termini in urine
samples to provide a diagnostic oligosaccharide signature
unique for each MPS subtype. These disease-specific oli-
gosaccharides can be used to monitor response to thera-
peutic interventions [48]. A fluorometric assay for
N-acetylgalactosamine-6-sulfate (GALNS) has been de-
veloped for the differential diagnosis of MPS IVA; how-
ever, the data suggest this will not be robust enough for
newborn screening [139]. Ongoing pilot studies of more
accurate tandem mass spectrometry assays and their
application to newborn screening have been described
[140]. Furthermore, advances to improve the accuracy of
newborn screening for LSDs by reducing the number of
false positive results are already underway [141].
Evidence suggests that although most patients develop
anti-drug antibodies to elosulfase alfa, immunogenicity
does not appear to impact efficacy or correlate with the
frequency of IARs [142, 143]. However, further studies
are required to fully understand the clinical implications
of anti-drug antibody (ADA) responses in MPS. A case
report in MPS II suggests that urinary GAG levels, mea-
sured by 1,9-dimethylmethylene blue (DMB) assay, may
be a biomarker for anti-idursulfase neutralising anti-
bodies [144]. This study highlights the importance of
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regular and frequent monitoring of urinary GAG levels
in patients with MPS II who are receiving ERT. The SC
highlighted the need for further investigation of bio-
markers and assays in MPS IVA/VI with timely publica-
tion of findings to inform guidance on monitoring. It
was suggested that when improved assays become avail-
able, consideration should be given to measurement of
total and neutralising antibodies every 6months in pa-
tients receiving ERT, with a rapid turnaround of labora-
tory results.
Future therapies, including gene therapy, small mol-
ecule therapy, and other anti-inflammatory agents such
as pentosan polysulphate (PPS) [145] are being investi-
gated for the treatment of MPS, and trials are ongoing.
The small molecule, odiparcil, restored a normal corneal
structure in the eye of a genetic mouse model of MPS
VI [146]. Given that ERT has a limited impact on bone
abnormalities and current therapies do not relieve skel-
etal symptoms, it will be important to assess the effect
of new therapies (such as gene therapy) on skeletal mani-
festations to address this unmet need. Tumour necrosis
factor alpha (TNF-α) inhibition has been suggested as a
potential adjunctive therapy to help manage pain in indi-
viduals receiving ERT and/or HSCT based on the observa-
tion that increased levels of TNF-α are associated with
pain and decreased physical function [147].
Across all therapies, an individualised dosing approach
would address one of the main challenges for the pharmaco-
logical treatment of patients with MPS. Treatment would be
greatly enhanced with the definition of minimal clinically
important differences for MPS and the development of im-
proved tools and/or biomarkers for monitoring response to
therapy. The development of MPS-specific patient-reported
outcome measures is also needed, along with formal stand-
ardisation and validation of health-related QoL tools for
the different MPS subtypes [148].
Conclusions
This manuscript provides robust evidence- and consen-
sus-driven guidance that can be used by all healthcare
professionals involved in the management of patients
with MPS IVA; results for MPS VI are detailed in the
companion article (Recommendations for the manage-
ment of MPS VI: systematic evidence- and consensus-
based guidance). The guidance is intended for use by
healthcare professionals that manage the holistic care of
patients with MPS with the intention to improve clinical-
and patient-reported outcomes and enhance patient qual-
ity of life. It recognised that the guidance provided repre-
sents a point in time and further research is required to
address current knowledge and evidence gaps. The SC
recommends that this guidance is reviewed and updated
within 5 years, or sooner if there are significant changes to
medical practice.
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